Insiders' Blog
Sponsored by: Subscribe to EasyStockAlerts.com Now & Get The News Before Everyone Else!
Celgene (CELG) Closes Up 8.4%
More News related to CELG
- Color on Baird's Upgrade of Celgene (CELG)
- Baird Upgrades Celgene (CELG) to Outperform
- Beacon Equity Issues Technical Trade Alerts on Market Movers: HPQ, WFC, RIMM, EBAY, CELG, AAPL, CME
- Cowen & Co Upgrades Celgene (CELG) to Outperform on Valuation
- Wall Street Media Presents Exclusive Conference Videos
More News related to SUPG
- SuperGen to Present Data at EORTC-NCI-AACR
- SuperGen to Present at UBS Global Life Sciences Conference on September 25, 2008
- SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
- SuperGen Granted Orphan Drug Designation for MP-470 in Glioblastoma Multiforme
- SuperGen (SUPG) Misses Q2 View By 2c
More News related to Insiders' Blog
- Sanford Bernstein Says Cable Operators (CMCSA, TWC) Likely To Face Higher Borrowing Costs
- AmTech Previews Google's (GOOG) Q3 Earnings; Reiterates Buy
- Citi Maintains 'Hold' Rating on Best Buy (BBY), Comments on Recent Meeting
- AmTech Sees Risks to Intel's (INTC) Margins in Future Quarters
- Citi Reiterates 'Buy' Rating on Altera Corp (ALTR), Remains Top Idea
Celgene (Nasdaq: CELG) closes up 8.4% today on volume that was over four times as strong as Celgene's average daily volume. Celgene is trading at its highest level since October 2007.
Celgene's shares rose as potential competitor to CELG's bone-marrow cancer treatment in Europe failed a late-stage clinical trial. Its rival SuperGen (Nasdaq: SUPG) said Dacogen didn't improve the survival rate of patients. SuperGen's stock closed down 14.63% to a low of $1.75.
Celgene Corporation is an integrated biopharmaceutical company.
SuperGen is a pharmaceutical company dedicated primarily to the discovery, development and commercialization of therapies to treat patients with cancer.
Sign up at EasyStockAlerts.com To Be Alerted To Your Breaking Stock News!
Related Categories
Insiders' BlogTrader Talk
Stocks Mentioned
-3.66Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
